Xanadu Bio Announces Agreement to Evaluate PACE Platform
Agreement leverages Xanadu’s novel poly(amine-co-ester), or PACE, a next generation polymer nanoparticle delivery platform that allows for specific and efficient delivery of nucleic acids, including mRNA and saRNA NEW HAVEN, Conn., January 10, 2025 — Xanadu Bio, a privately held biotechnology company focusing on next generation delivery of messenger RNA (mRNA), self-amplifying RNA (saRNA), and […]
Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission
~ Company licenses PACE, a next generation polymeric nanoparticle delivery platform, and options intranasal PACE/Spike mRNA and Spike recombinant protein vaccine boosters for the treatment of aerosolized viruses; initially targeting SARS CoV-2 ~ ~ Technologies developed in the laboratories of Yale University Professors Mark Saltzman and Akiko Iwasaki ~ ~ Preclinical data demonstrates intranasal PACE/Spike […]